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Abstract
Background: Atherosclerosis underlies the major pathophysiological mechanisms of coronary
heart disease (CHD), and inflammation contributes to all phases of atherosclerosis. C-reactive
protein (CRP), a sensitive, but nonspecific marker of inflammation has been shown to play
proatherogenic roles in the process of atherosclerosis. Our previous report showed that
rs2794521 (-717A>G), located in the promoter of the CRP gene, was independently associated
with CHD in Chinese subjects. In the present study, we tried to investigate the biological
significance of this genetic variation in vitro.
Methods: The influence of G to A substitution at the site of rs2794521 on the transcriptional
activity of the promoter of the CRP gene was assessed by luciferase reporter assay, and protein
binding to the site of rs2794521 was detected by EMSA assay.
Results: The G to A exchange at the site of rs2794521 resulted in an increased transcriptional
activity of the promoter of CRP gene, and glucocorticoid receptor (GR) protein factor bound
drastically differently to the A and G alleles at the site of rs2794521.
Conclusion: These results provided functional evidence supporting the association of the SNP
rs2794521 of the CRP gene with CHD probably through regulating the expression level of CRP by
different variations of rs2794521.
Background
The global burden of cardiovascular disease (CVD) repre-
sents the highest cause of mortality and one of the highest
causes of morbidity both in high-income and low/mid-
dle-income countries[1,2]. More than 7 million of the
almost 17 million cardiovascular deaths each year is a
result of coronary heart disease (CHD). According to a
report issued by the World Health Organization, CHD is
the leading cause of death in men and women aged ≥60
years. Prevailing evidence has shown that CHD is a com-
plex disease where both multiple minor genetic and envi-
ronmental factors interact [3].
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Atherosclerosis underlies the major pahthophysiological
mechanisms of CHD[4]. Originally considered a disorder
of lipid metabolism, atherosclerosis is now regarded as an
inflammatory disease [5-7]. Inflammation contributes to
all phases of atherosclerosis, from fatty streak initiation to
cardiovascular disease events. Researches into the inflam-
matory nature of atherosclerosis suggested that inflamma-
tory-response proteins, particularly acute-phase reactants,
might be involved in the pathogenesis of developing
atherosclerosis. C-reactive protein (CRP), a sensitive, but
nonspecific marker of inflammation (an acute-phase reac-
tant) [8] has been shown to play proatherogenic roles in
the process of atherosclerosis via effects on monocytes
and endothelial cells: CRP directly induced the expression
of adhesion molecules and monocyte chemoattractant
protein-1 (MCP-1) by endothelial cells [9,10], increased
plasminogen activator inhibitor-1 expression and activity
in endothelial cells [11], decreased eNOS mRNA, protein
abundance and enzyme activity in endothelial cells, and
preincubation of cells with CRP also significantly
increased the adhesion of monocytes to endothelial cells
[12]. CRP deposited in the arterial wall in early atheroscle-
rotic lesions [13], and might contribute to the formation
of foam cells in atherosclerotic lesions by causing the
aggregation of LDL molecules that are then taken up by
macrophages through a CD32-independent pathway
[14]. Family and twin studies have estimated that genetic
factors accounted for 35–40% of the variance of CRP lev-
els [15-17], and polymorphisms in the CRP gene have
consistently been associated with basal CRP levels in both
men and women[18,19]. Genetic variants within the CRP
gene are related to the observed CRP response during and
after acute coronary syndromes [20]or acute ischemic
stroke/TIA[21].
Our previous report showed that rs2794521 (-717A>G)
located in the promoter of the CRP gene was independ-
ently associated with CHD in Chinese subjects[4], the fre-
quency of A allele carriers was significantly higher in
patients than in controls, and individuals carrying A allele
had an approx. 6.8-fold higher risk of developing CHD
compared with those not carrying this allele. However,
the influence of G to A substitution at the site of
rs2794521 on the transcriptional activity of the promoter
of the CRP gene is unknown, in particular a difference for
nuclear proteins binding to A or G allele at the site of
rs2794521 has not been studied. In the present study, the
biological relevance of the SNP rs2794521 significantly
associated with CHD in Chinese subjects[4] was studied
by various functional assays in vitro.
Methods
Construction of luciferase reporter gene
The genomic sequence of the CRP gene containing the site
of rs2794521 was amplified by PCR from 1 individual
homozygous for the A allele and 1 individual
homozygous for the G allele. The PCR primers were tai-
lored to incorporate a Kpn I site at the 5' end and an Xho
I site at the 3' end of the amplified fragments. These 915-
base pair (bp) genomic fragments, corresponding to nt -
858 to +57 of the CRP promoter region, were then puri-
fied, digested with the two designated restriction endonu-
cleases, and further subcloned into the Kpn I and Xho I
sites of the firefly luciferase expressing pGL3-basic vector
(Promega, USA) to create two plasmids: pGL3-basic-A
and pGL3-basic-G. Both constructs were sequenced to ver-
ify that the only ambiguity was the polymorphic site.
Cell cultures, transfections and luciferase assays
Human HepG2 cells were grown in Dulbecco's modified
Eagle medium (DMEM) medium with 10% fetal bovine
serum (FBS), 5% heat-inactivated donor horse serum and
10 μg/ml of penicillin/streptomycin at 37°C and 5% CO2.
Cells were seeded at a density of 2.5 × 105 cells per well in
a 12-well plate 24 hours prior to transfection in medium
without antibiotics. Transfections were performed with
Lipofectamine 2000 (Invitrogen, USA) according to the
manufacturer's instructions. Approximately 2 μg of the
luciferase reporter gene were cotransfected with 0.5 μg of
pRL-TK (Renilla luciferase, Promega, USA) as an internal
control for variations in transfection efficiency. Transfec-
tion using pGL3-basic vector without an insert was used as
a negative control. The transfected cells were harvested
after 24 hours, and the luciferase activity was measured
with Dual-Luciferase Reporter Assay System (Promega,
USA) using a luminometer (TD-20, Turner Designs,
Sunny vale, USA).
Preparation of nuclear extracts
Nuclear extracts from HepG2 cells were prepared with NE-
PER@Nuclear and Cytoplasmic Extraction Reagents kit
(Pierce, Rockford, IL, USA) according to the manufacture's
instructions. Protein concentrations were determined by a
bicinchoninic acid (BCA) assay (Pierce, USA), and the
nuclear extracts were stored at -80°C.
Electrophoretic mobility shift assay and supershift assays
Synthetic double-stranded oligonucleotide probes(A:
AACCAAACACCGCATGTTCTCACTC; and G: AAC-
CAAACACCGCGTGTTCTCACTC) corresponding to the
genomic sequence in the promoter of the CRP gene with
either A or G allele at the rs2794521 site were labeled with
biotin (Shanghai Sangon Biological Engineering Technol-
ogy and Services Co., Ltd., Shanghai, China). Electro-
phoretic mobility shift assays were performed by using the
LightShift™ Chemiluminescent EMSA kit (Pierce, USA).
For each gel shift reaction (20 μl), a total of 20 fmol
biotin-labeled probe was combined with 15 μg nuclear
extract prepared from HepG2 cells, 1 μg poly (dI-dC), and
1×binding buffer. For competition assays, a 200-foldBMC Medical Genetics 2009, 10:73 http://www.biomedcentral.com/1471-2350/10/73
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molar excess of unlabeled A or G probe was pre-incubated
for 5 minutes at room temperature with nuclear extracts
before the addition of the labeled probe. For supershift
experiments, antibody specific for glucocorticoid receptor
(GR) or nonspecific rabbit IgG (Santa Cruz Biotechnol-
ogy) was used. The antibody or rabbit IgG (2 μg) was incu-
bated with nuclear extract for 1 hr at 4°C, followed by an
additional incubation for 20 minutes at room tempera-
ture with a labeled probe A. The reaction mixture was
resolved on a non-denaturing 6% acrylamide gel in 0.5×
TBE buffer, the electrophoresised binding reactions were
then transferred to nylon membrane, and cross-linking
was performed for 5 minutes with a UV cross linker. The
signal of the biotin-labeled DNA bound to the membrane
was detected with a LightShift Chemiluminescent EMSA
Kit (Pierce, USA) according to the manufacturer's instruc-
tions.
Statistical analysis
Luciferase assay data were assessed by Student's t-test
using SigmaPlot (SPSS) and a P-value less than 0.05 was
considered statistically significant.
Results
Allele-specific effect of the rs2794521 on transcriptional 
activity
We considered that transcriptional regulation elements
might be located in the promoter region of the CRP gene
and performed biological assays to investigate whether
the rs2794521 SNP located in the promoter of the CRP
gene had a direct effect on promoter transcriptional activ-
ity. A genomic fragment of the CRP gene carrying either
the A or G allele at the site of rs2794521 was inserted into
the Hind III and Kpn I sites of the firefly luciferase express-
ing pGL3-basic vector (Fig. 1A). The activity of these luci-
ferase reporter gene constructs was assessed in transient
transfection assays in HepG2 cells. The luciferase activity
of the variant A construct was 1- to 2-fold higher than that
of the common G construct (P < 0.005; Fig. 1B). This
result clearly indicated that transcriptional activity of the
promoter of CRP gene containing the A allele was higher
than that of the promoter of CRP gene containing the G
allele.
Allele-specific effect of the rs2794521 on binding of 
nuclear proteins to the promoter of the CRP gene
To elucidate specific nuclear factors that might bind the
disease-susceptible allele, we analyzed the sequence
around rs2794521 site using TRANSFAC software, and
found that the sequence containing G allele at the site of
rs2794521 is a not well-matched GR binding motif, and
the G to A exchange at the site of rs2794521 resulted in a
well-matched GR binding motif. Therefore, we performed
electrophoretic mobility shift assays to determine the
nuclear factors that might bind to oligonucleotides corre-
sponding to genomic sequence of the A or G allele of
rs2794521, and to determine whether the binding of the
transcription factor(s) differed for the A and G alleles. The
GR binds to a glucocorticoid response element (GRE) as a
monomer and a dimer as previously reported[22], and the
incubation of nuclear extract of HepG2 cells with probe A
showed two kinds of DNA-protein complex with the GR
motif oligonucleotide probes, which probably represent
monomer (Band 2) and dimer (Band 1) of GR (Lane 2).
The incubation of nuclear extract of HepG2 cells with
probe G showed a large increase in the dimer (Lane 5,
band 1), and a dramatic reduction in monomer (Lane 5,
band 2). These shifted bands could be completely abol-
ished by 200-fold unlabeled A or G probe (Fig. 2, lane 3
and 6), indicating specific binding of nuclear protein(s) to
the oligonucleotide corresponding to genomic sequence
of A or G allele.
Because the G to A exchange at the site of rs2794521
resulted in a well-matched GR binding motif and the GR
bound to both the A and G alleles, we further performed
supershift assay to confirm the identity of the DNA-bind-
ing protein using the probe A and the antibody specific for
GR or nonspecific rabbit IgG. The DNA-protein complex
was successfully supershifted with the anti-GR antibody
(Fig. 3, lane 3), but not the rabbit IgG (Fig. 3, lane 4).
Taken together, these results clearly demonstrate that SNP
rs2794521 in the promoter of CRP gene is within a GR-
binding motif, and the A to G substitution results in dif-
ferent binding affinity for monomer or dimer of GR pro-
tein.
Discussion
It is well known that CHD is a complex disease where
both multiple minor genetic and environmental factors
interact[3]. Our previous report[4] found that the A allele
of rs2794521 located in the promoter region of the CRP
gene was independently associated with CHD in Chinese
subjects. Individuals carrying the A allele had an approx.
6.8-fold higher risk of developing CHD compared with
those not carrying this allele. This finding has been con-
firmed, as the same SNP was found to correlate with
occurrence of myocardial infarction or thromboembolic
stroke in the Physician's Health Study[19]. In the present
study, we found that transcriptional activity of the pro-
moter of CRP gene containing the A allele was higher than
that of the promoter of CRP gene containing the G allele.
Among several case-control studies involving the SNP
rs2794521 with CHD [4,19,21,23], our present study is
the first to confirm that the SNP rs2794521 is to be func-
tional.
E. Ben-Assayag et al. reported that -717A>G was associ-
ated with triggered CPR levels during acute stroke/
TIA[21]. This study indicated that -717A>G located at theBMC Medical Genetics 2009, 10:73 http://www.biomedcentral.com/1471-2350/10/73
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promoter region of the CRP gene was far more than just a
marker associated with CHD, but might have native bio-
logical function. Our present study showed an increased
transcriptional activity of the promoter of the CRP gene
driven by A allele, therefore we deduced that the associa-
tion of -717A>G with altered plasma levels of CRP[21]
might be due to the exchange of G to A allele at the site of
rs2794521, thus resulting in the increase of the CRP levels
during some stimulating conditions. Additional studies
aimed to confirm this finding are warranted.
Nuclear protein factor(s) plays important roles in the reg-
ulation of gene expression. There is a well-matched GR
binding motif at the site of rs2794521 after the exchange
of G to A allele. Our EMSA assay found that two kinds of
DNA-protein complex with oligonucleotide probe A cor-
responding to genomic sequence of the A allele, which
probably represent monomer (Band 2) and dimer (Band
1) of GR (Lane 2) as previously reported[22], but a large
increase in the dimer (Lane 5, band 1), and a dramatic
reduction in monomer (Lane 5, band 2) binding to oligo-
nucleotide probe G corresponding to genomic sequence
of the G allele. The EMSA experiment showed that the
binding of GR to the A and G alleles differed drastically.
The supershift EMSA was then performed with only one
probe, probe A, because of the higher similarity of probe
A sequence to GR binding motif. The supershift EMSA
experiment showed that it is GR protein that bound to the
A allele of rs2794521. This indicated that the binding of
GR factor to the two alleles of rs2794521 was drastically
different. But it is unknown whether the different binding
of GR to the two alleles of rs2794521 accounts for the dif-
ferent transcriptional activity of the promoter of the CRP
gene derived by A or G allele. GR can contribute to the reg-
ulation of gene transcription in different ways[24]. Unu-
sually, glucocorticoids bind to the GR, which are
translocated to the nucleus and the GR functions as dimer.
However, the activated GR may bind to other nuclear
receptors forming heterodimers, and the heterodimers
bind to GREs or as yet unknown DNA elements thereby
affecting the transcription rate of glucocorticoid-respon-
sive genes [24]. According to the reference [22,24] and our
results, we deduced that the monomer of GR might bind
to the A allele of rs2794521, and affect the transcription
activity of the promoter of the CRP gene through the for-
mation of heterodimers with other nucleus receptors,
which needs to be further studied.
Conclusion
In summary, we found that the G to A exchange at the site
of rs2794521 resulted in an increased transcriptional
activity of the promoter of CRP gene, and the GR protein
factor bound drastically differently to the A and G alleles.
These molecular data provided functional evidence of
sceptible allele) to A (susceptible allele) at the site of rs2794521 located in the promoter of CRP gene enhanced transcriptional  activity of the promoter of CRP in HepG2 cells Figure 1 (see previous page)
Allelic change from G (nonsusceptible allele) to A (susceptible allele) at the site of rs2794521 located in the 
promoter of CRP gene enhanced transcriptional activity of the promoter of CRP in HepG2 cells. A, schematic 
representation of the plasmid constructs. 915 bp fragment of CRP promoter (-858/+57) containing either the A or G allele (i.e. 
A and G promoter, respectively) was inserted in the pGL3-basic luciferase expression vector. Empty vector: pGL3-basic vec-
tor. B, HepG2 cells were contransfected with individual firefly luciferase (FLuc)expressing plasmid (A promoter, G promoter, 
empty vector) and pRL-TK as described in Materials and Methods. Cells were harvested after 24 hours, and relative luciferase 
activity (FLuc/Renilla luciferase) was determined. Fold luciferase activity of the variant A construct was 1- to 2-fold higher than 
that of the common G construct (P < 0.005). Data are present as fold-induction compared with promoter vector without 
insert. Bares are mean ± standard error of 3 different experiments, each performed in dulplicate.
Alleles of rs2794521 differentially bind transcription factor(s) Figure 2
Alleles of rs2794521 differentially bind transcription 
factor(s). EMSA was performed by using biotin-labeled 
probe A or probe G with HepG2 cell nuclear extract, with 
or without competition from unlabeled probe A or probe G. 
The GR binds to a GRE as a monomer and a dimer as previ-
ously reported, and the incubation of nuclear extract of 
HepG2 cells with probe A showed two kinds of DNA-pro-
tein complex with the GR motif oligonucleotide probes, 
which probably represent monomer (Band 2) and dimer 
(Band 1) of GR (Lane 2). The incubation of nuclear extract of 
HepG2 cells with probe G showed a large increase in the 
dimer (Lane 5, band 1), and a dramatic reduction in mono-
mer (Lane 5, band 2). The experiments were repeated three 
times with similar results.BMC Medical Genetics 2009, 10:73 http://www.biomedcentral.com/1471-2350/10/73
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association of a common rs2794521 of the CRP gene with
CHD in Chinese Han population probably through regu-
lating the expression level of CRP by different variations
of rs2794521. Nonetheless, additional research will be
required to better define the functional significance of this
variant and to clarify the mechanism of the association of
inflammatory protein involving the CRP gene with CHD.
Abbreviations
BCA: bicinchoninic acid; bp: base pair; CHD: coronary
heart disease; CVD: cardiovascular disease; CRP: C-reac-
tive protein; EMSA: electrophoretic mobility shift assay;
PCR: polymerase chain reaction; SNP: single nucleotide
polymorphism.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
LYW and HFL carried out the molecular biological studies.
XFL, YL and SF CH performed the statistical analysis. LYW
and DFG conceived of the study, and participated in its
design and coordination and helped to draft the manu-
script. All authors read and approved the final manu-
script.
Acknowledgements
We thank Pro. Lanying Chen for her nice suggestion for the manuscript. 
This work was supported by National Basic Research Program of China 
(Grant No. 2006CB503805), National High Technology Research and 
Development Program of China (Grant No. 2006AA02Z170), Academic 
Capacity Development Program of Beijing Municipal Commission of Educa-
tion (Grant No. XK100230447) and National Natural Science Foundation 
of China (Grant No. 30600357).
References
1. WHO Global Strategy on Diet, Physical Activity and Health.
Cardiovascular disease: prevention and control   [http://
www.who.int/dietphysicalactivity/publications/facts/cvd/en/]
2. Lopez A, Mathers CD, Ezzati M, Jamison DT, Murray CJL: Global
Burden of Disease and Risk Factors.  NY, Oxford University
Press; 2006. 
3. Stephens JW, Humphries SE: The molecular genetics of cardio-
vascular disease: clinical implications.  J Intern Med 2003,
253:120-127.
4. Chen J, Zhao J, Huang J, Su S, Qiang B, Gu D: -717A>G polymor-
phism of human C-reactive protein gene associated with
coronary heart disease in ethnic Han Chinese: the Beijing
atherosclerosis study.  J Mol Med 2005, 83:72-78.
5. Hunninghake DB: Cardiovascular disease in chronic obstruc-
tive pulmonary disease.  Proc Am Thorac Soc 2005, 2:44-49.
6. Ross R: Atherosclerosis: an inflammatory disease.  N Engl J Med
1999, 340:115-126.
7. Hansson GK: Inflammation, atherosclerosis, and coronary
artery disease.  N Engl J Med 2005, 352:1685-1695.
8. Masiá M, Bernal E, Padilla S, Graells ML, Jarrín I, Almenar MV, Molina
J, Hernández I, Gutiérrez F: The role of C-reactive protein as a
marker for cardiovascular risk associated with antiretroviral
therapy in HIV-infected patients.  Atherosclerosis 2007,
195:167-171.
9. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect
of C-reactive protein on human endothelial cells.  Circulation
2000, 102:2165-2168.
10. Pasceri V, Cheng JS, Willerson JT, Yeh ET: Modulation of C-reac-
tive protein-mediated monocyte chemoattractant protein-1
induction in human endothelial cells by anti-atherosclerosis
drugs.  Circulation 2001, 103:2531-2534.
11. Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasmino-
gen activator inhibitor-1 expression and activity in human
aortic endothelial cells: implications for the metabolic syn-
drome and atherothrombosis.  Circulation 2003, 107:398-404.
12. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I: Demonstration
that C-reactive protein decreases eNOS expression and bio-
activity in human aortic endothelial cells.  Circulation 2002,
106:1439-1441.
13. Torzewski J, Torzewski M, Bowyer DE, Fröhlich M, Koenig W,
Waltenberger J, Fitzsimmons C, Hombach V: C-reactive protein
frequently colocalizes with the terminal complement com-
plex in the intima of early atherosclerotic lesions of human
coronary arteries.  Arterioscler Thromb Vasc Biol 1998,
18:1386-1392.
14. Fu T, Borensztajn J: Macrophage uptake of low-density lipopro-
tein bound to aggregated C-reactive protein: possible mech-
anism of foam-cell formation in atherosclerotic lesions.
Biochem J 2002, 366:195-201.
15. Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN, Eckfeldt
JH, Tracy RP: Familial and genetic determinants of systemic
markers of inflammation: the NHLBI family heart study.
Atherosclerosis 2001, 154:681-689.
16. Retterstol L, Eikvar L, Berg K: A twin study of C-Reactive Protein
compared to other risk factors for coronary heart disease.
Atherosclerosis 2003, 169:279-282.
17. MacGregor AJ, Gallimore JR, Spector TD, Pepys MB: Genetic
effects on baseline values of C-reactive protein and serum
amyloid a protein: a comparison of monozygotic and dizy-
gotic twins.  Clin Chem 2004, 50:130-134.
Supershift assays confirmed the identification of the DNA- binding protein Figure 3
Supershift assays confirmed the identification of the 
DNA-binding protein. Supershift assays with biotin-
labeled 25 bp oligonuceotides containing the A allele of 
rs2794521 and nuclear extracts from HepG2 cells in the 
presence of anti-GR (Lane 3) or normal IgG (Lane 4). Labeled 
oligonucleotides incubated without the nuclear extracts 
were included as negative controls (Lane 1). 2 μg of anti-GR 
antibody or normal IgG was preincubated with the nuclear 
extract for 1 hour at 4°C before the labeled probe was 
added. The experiments were repeated three times with 
similar results.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Genetics 2009, 10:73 http://www.biomedcentral.com/1471-2350/10/73
Page 7 of 7
(page number not for citation purposes)
18. Suk HJ, Ridker PM, Cook NR, Zee RY: Relation of polymorphism
within the C-reactive protein gene and plasma CRP levels.
Atherosclerosis 2005, 178:139-145.
19. Miller DT, Zee RY, Suk Danik J, Kozlowski P, Chasman DI, Lazarus R,
Cook NR, Ridker PM, Kwiatkowski DJ: Association of common
CRP gene variants with CRP levels and cardiovascular
events.  Annals of Human Genetics 2005, 69:623-638.
20. Suk Danik J, Chasman DI, Cannon CP, Miller DT, Zee RY, Kozlowski
P, Kwiatkowski DJ, Ridker PM: Influence of Genetic Variation in
the C-Reactive Protein Gene on the Inflammatory Response
During and After Acute Coronary Ischemia.  Annals of Human
Genetics 2006, 70:705-716.
21. Ben-Assayag E, Shenhar-Tsarfaty S, Bova I, Berliner S, Shopin L, Peretz
H, Usher S, Shapira I, Bornstein NM: Triggered C-reactive pro-
tein (CRP) concentrations and the CRP gene -717A>G poly-
morphism in acute stroke or transient ischemic attack.
European Journal of Neurology 2007, 14:315-320.
22. Segard-Maurel I, Rajkowski K, Jibard N, Schweizer-Groyer G, Baulieu
EE, Cadepond F: Glucocorticosteroid receptor dimerization
investigated by analysis of receptor binding to glucocorticos-
teroid responsive elements using a monomer-dimer equilib-
rium model.  Biochemistry 1996, 35:1634-1642.
23. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A,
Sharma P, Lowe GD, World MJ, Humphries SE, Hingorani AD:
Human CRP Gene Polymorphism Influences CRP Levels:
Implications for the Prediction and Pathogenesis of Coro-
nary Heart Disease.  Arterioscler Thromb Vasc Biol 2003,
23:2063-2069.
24. De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M: Brain corticoster-
oid receptor balance in health and disease.  Endocr Rev 1998,
19:269-301.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/10/73/pre
pub